Dimensional Fund Advisors LP Raises Holdings in Amgen Inc. $AMGN

Dimensional Fund Advisors LP boosted its holdings in shares of Amgen Inc. (NASDAQ:AMGN) by 5.1% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 3,178,590 shares of the medical research company’s stock after acquiring an additional 154,664 shares during the quarter. Dimensional Fund Advisors LP owned about 0.59% of Amgen worth $896,843,000 at the end of the most recent quarter.

Several other large investors have also modified their holdings of AMGN. Legacy Investment Solutions LLC acquired a new position in Amgen in the second quarter valued at about $27,000. Evelyn Partners Investment Management LLP purchased a new stake in shares of Amgen in the 2nd quarter valued at approximately $32,000. Howard Hughes Medical Institute acquired a new position in shares of Amgen in the 2nd quarter worth approximately $32,000. Cloud Capital Management LLC purchased a new position in shares of Amgen during the 3rd quarter worth approximately $34,000. Finally, Nvwm LLC increased its holdings in Amgen by 893.3% in the 2nd quarter. Nvwm LLC now owns 149 shares of the medical research company’s stock valued at $42,000 after purchasing an additional 134 shares during the last quarter. Institutional investors and hedge funds own 76.50% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research firms have commented on AMGN. HSBC restated a “buy” rating and set a $425.00 price target on shares of Amgen in a research note on Wednesday, December 10th. Royal Bank Of Canada raised their target price on Amgen from $335.00 to $360.00 and gave the company an “outperform” rating in a report on Wednesday, February 4th. DZ Bank boosted their price target on shares of Amgen from $335.00 to $364.00 in a research note on Monday, November 10th. Citigroup increased their price target on shares of Amgen from $315.00 to $345.00 and gave the stock a “neutral” rating in a research report on Wednesday, February 4th. Finally, Mizuho lifted their price objective on shares of Amgen from $280.00 to $295.00 and gave the company an “outperform” rating in a report on Tuesday, February 10th. One research analyst has rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating, eleven have assigned a Hold rating and two have given a Sell rating to the stock. Based on data from MarketBeat, Amgen presently has a consensus rating of “Moderate Buy” and an average price target of $351.76.

Amgen Stock Down 2.3%

Shares of NASDAQ:AMGN opened at $377.00 on Wednesday. The company has a quick ratio of 0.90, a current ratio of 1.14 and a debt-to-equity ratio of 5.78. Amgen Inc. has a fifty-two week low of $261.43 and a fifty-two week high of $391.29. The stock has a market cap of $203.23 billion, a price-to-earnings ratio of 26.49, a price-to-earnings-growth ratio of 3.83 and a beta of 0.45. The firm’s 50 day moving average price is $350.89 and its 200 day moving average price is $321.17.

Amgen (NASDAQ:AMGN) last announced its quarterly earnings data on Tuesday, February 3rd. The medical research company reported $5.29 earnings per share for the quarter, beating analysts’ consensus estimates of $4.76 by $0.53. The business had revenue of $9.87 billion for the quarter, compared to analyst estimates of $9.46 billion. Amgen had a net margin of 20.98% and a return on equity of 148.37%. The company’s revenue was up 8.6% on a year-over-year basis. During the same period last year, the business earned $5.31 EPS. Amgen has set its FY 2026 guidance at 21.600-23.000 EPS. As a group, equities research analysts predict that Amgen Inc. will post 20.62 earnings per share for the current fiscal year.

Amgen Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, March 6th. Stockholders of record on Friday, February 13th will be given a dividend of $2.52 per share. The ex-dividend date of this dividend is Friday, February 13th. This represents a $10.08 annualized dividend and a dividend yield of 2.7%. This is an increase from Amgen’s previous quarterly dividend of $2.38. Amgen’s payout ratio is currently 70.84%.

Trending Headlines about Amgen

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: Amgen hit an annual high within a Nasdaq-100 index rally, highlighting strong recent price momentum and renewed investor interest that can support upside if broader tech/healthcare flows continue. Amgen (NASDAQ:AMGN) Hits Annual High Within The Nasdaq 100 Index Rally
• Positive Sentiment: Oppenheimer named AMGN among top momentum stocks, which can attract short-term inflows from momentum- and quant-driven funds. AAPL, AA, BKR, and AMGN are among the top stocks for momentum, says Oppenheimer
• Positive Sentiment: Industry market research points to long-term growth in asthma and biologics markets — an expanding opportunity set for Amgen’s respiratory and biologics franchises if its pipeline and commercialization execute. 7MM Asthma Market Insights, Epidemiology, and Market Forecast Report 2022-2036
• Neutral Sentiment: Amgen presented at the TD Cowen healthcare conference (transcript available) — such presentations can update investors on commercial performance and pipeline timing but typically move stock only when new guidance or surprises appear. Amgen Inc. (AMGN) Presents at TD Cowen 46th Annual Health Care Conference Transcript
• Neutral Sentiment: Coverage pieces from Zacks and Yahoo signal increased retail/institutional attention — visibility that can amplify both rallies and pullbacks depending on order flow. Amgen Inc. (AMGN) is Attracting Investor Attention: Here is What You Should Know Amgen Inc. (AMGN) is Attracting Investor Attention: Here is What You Should Know
• Neutral Sentiment: Reported short-interest entries in the feed show anomalous “0 shares / NaN” data — this looks like a data error and should not be treated as meaningful evidence of rising short pressure without corroboration from an official short-interest report. (Monitor official short-interest filings for clarity.)
• Negative Sentiment: Sanofi received an orphan-drug designation for Wayrilz in IgG4-related disease in Japan — a regulatory win for a competitor that could create niche competition in specific indications and modestly pressure expectations where overlap exists. Sanofi’s Wayrilz Gets Orphan Drug Tag for IgG4-Related Disease in Japan
• Negative Sentiment: After reaching an annual high, the stock’s pullback looks consistent with profit-taking and sector rotation; that technical unwind can outweigh near-term fundamental positives if macro sentiment turns risk-off.

Amgen Profile

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.